Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-524-687"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech²
dcterms:Date	"2012-10-23"^^xsd:date²
dcterms:Is Part Of	lp_eu:Explanations of vote²
dcterms:Language	"de"^^xsd:language²
lpv:document identification number	"en.20121023.45.2-524-687"²
lpv:hasSubsequent	lp_eu:2012-10-23-Speech-2-524-750²
lpv:speaker	lp:Angelika Werthmann²
lpv:spokenAs	member; PETI (2012-10-22--2014-06-30)³ substitute; Delegation for relations with Switzerland and Norway and to the EU-Iceland Joint Parliamentary Committee and the European Economic Area (EEA) Joint Parliamentary Committee (2012-09-07--2014-04-07)³ member; Delegation for relations with the countries of South Asia (2009-09-16--2014-06-30)³ unknown; - (2010-07-14--2014-06-30)³ member; ALDE (2012-07-04--2014-04-07)³ member; BUDG (2012-01-19--2014-06-30)³ substitute; FEMM (2012-09-10--2014-04-07)³
lpv:translated text	"The EGF exists in order to provide additional support for workers who are suffering from the impacts of globalisation and to facilitate their re-integration into the labour market. This application from Sweden has been reviewed. It relates to 987 persons affected by redundancies. The Swedish authorities argue that, in the light of the fact that Sweden had a strong position in medical research, the collective redundancies in AstraZeneca had not been expected. The worsening situation in the pharmaceutical sector was more severe than anticipated and ultimately resulted in these redundancies."@en¹

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph